Clinical Trials Browser

INDUSTRY × Gastro-enteropancreatic neuroendocrine tumor × Clear all

Gastro-enteropancreatic neuroendocrine tumor, Lymphoma, Follicular

NCT03833700 2026-02-27

A Study of E7386 in Participants With Advanced Solid Tumor Including Colorectal Cancer (CRC)

Gastro-enteropancreatic neuroendocrine tumor, Digestive System Neoplasms, Carcinoma, Hepatocellular, Colorectal Neoplasms, Desmoid Tumors, Adrenocortical Carcinoma

NCT04711135 2026-02-12

NETTER-P

Phase 2 Active not recruiting

11 enrolled 14 charts 1 FDA

CNSEndocrineGastrointestinalNET

Gastro-enteropancreatic neuroendocrine tumor, Paraganglioma, Pheochromocytoma

NCT03972488 2026-01-21

NETTER-2

Phase 3 Active not recruiting

226 enrolled 14 charts

EndocrineGastrointestinalNET

Gastro-enteropancreatic neuroendocrine tumor

NCT05477576 2026-01-20

ACTION-1

Phase 3 Recruiting

288 enrolled

EndocrineGastrointestinalNET

Gastro-enteropancreatic neuroendocrine tumor, Carcinoid Tumor, Adenoma, Islet Cell, Neuroendocrine Tumors

NCT06441331 2025-12-17

KinLET

Phase 1 Recruiting

20 enrolled

CNSEndocrineGastrointestinalLymphoidNETSarcoma

Gastro-enteropancreatic neuroendocrine tumor, Lymphoma, Rhabdomyosarcoma, Central Nervous System Neoplasms, Neuroectodermal Tumors, Primitive, Peripheral, Neuroendocrine Tumors

NCT05636618 2025-11-24

Targeted Alpha-Particle Therapy for Advanced Somatostatin Receptor Type 2 (SSTR2) Positive Neuroendocrine Tumors

Phase 1/2 Recruiting

260 enrolled

CNSEndocrineGastrointestinalNET

Gastro-enteropancreatic neuroendocrine tumor, Paraganglioma, Pheochromocytoma, Neuroendocrine Tumors

NCT05050942 2025-11-06

SORENTO

Phase 3 Active not recruiting

332 enrolled

EndocrineGastrointestinalNET

Gastro-enteropancreatic neuroendocrine tumor

NCT04727723 2025-10-03

REAL-LU

Active not recruiting

164 enrolled

EndocrineGastrointestinalNET

Gastro-enteropancreatic neuroendocrine tumor, Neuroendocrine Tumors

NCT04919226 2025-09-10

COMPOSE

Phase 3 Active not recruiting

259 enrolled

EndocrineGastrointestinalNET

Gastro-enteropancreatic neuroendocrine tumor, Neuroendocrine Tumors

NCT07165132 2025-09-10

Study of RYZ401 in Subjects With Solid Tumors Expressing SSTRs.

Phase 1 Not yet recruiting

104 enrolled

EndocrineGastrointestinalNET

Gastro-enteropancreatic neuroendocrine tumor, Carcinoid Tumor, Adenoma, Islet Cell, Neuroendocrine Tumors

NCT02611024 2025-07-09

Pharmacokinetic Study of Lurbinectedin in Combination With Irinotecan in Patients With Selected Solid Tumors

Phase 1/2 Completed

316 enrolled

CNSEndocrineGastrointestinalGynecologicNETOther solid neoplasmSarcomaThoracic

Gastro-enteropancreatic neuroendocrine tumor, Carcinoma, Ovarian Epithelial, Glioblastoma, Mesothelioma, Neoplasms, Sarcoma, Stomach Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Neuroendocrine Tumors

NCT04524442 2025-01-24

Post-Authorization Safety Study (PASS) of LysaKare® in Adult Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET) Patients

Phase 4 Completed

42 enrolled 11 charts

EndocrineGastrointestinalNET

Gastro-enteropancreatic neuroendocrine tumor, Carcinoid Tumor, Neuroendocrine Tumors

NCT06253897 2024-12-24

BackSOM

Completed

20 enrolled

EndocrineGastrointestinalNET

Gastro-enteropancreatic neuroendocrine tumor, Acromegaly

NCT04852679 2024-10-01

PALACE

Phase 3 Completed

43 enrolled 16 charts

EndocrineGastrointestinalNET

Gastro-enteropancreatic neuroendocrine tumor

NCT05997056 2024-07-16

Trial of Nab-sirolimus in Patients With Well-differentiated Neuroendocrine Tumors (NETs) of the Gastrointestinal Tract, Lung, or Pancreas Who Have Not Received Prior Treatment With mTOR Inhibitors

Phase 2 Recruiting

21 enrolled

EndocrineGastrointestinalNET

Gastro-enteropancreatic neuroendocrine tumor, Adenoma, Islet Cell, Neuroendocrine Tumors

NCT03220217 2021-01-14

To Evaluate the Optimal Dose of 68Ga-OPS202 as a PET (Positron Emission Tomography) Imaging Agent in Subjects With Gastroenteropancreatic Neuroendocrine Tumour (GEP-NET)

Phase 2 Completed

29 enrolled 18 charts

EndocrineGastrointestinalNET

Gastro-enteropancreatic neuroendocrine tumor

NCT01994213 2019-01-22

A Study of Famitinib in Patients With Advanced or Metastatic Gastroenteropancreatic Neuroendocrine Tumor

Phase 2 Terminated

53 enrolled

EndocrineGastrointestinalNET

Gastro-enteropancreatic neuroendocrine tumor

NCT03017690 2018-12-21

Lanreotide and Octreotide Long Acting Release (LAR) for Patients With Advanced Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)

Completed

22 enrolled

EndocrineGastrointestinalNET

Gastro-enteropancreatic neuroendocrine tumor

Clinical Trials

NETTER-3

A Study of E7386 in Participants With Advanced Solid Tumor Including Colorectal Cancer (CRC)

NETTER-P

NETTER-2

ACTION-1

KinLET

Targeted Alpha-Particle Therapy for Advanced Somatostatin Receptor Type 2 (SSTR2) Positive Neuroendocrine Tumors

SORENTO

REAL-LU

COMPOSE

Study of RYZ401 in Subjects With Solid Tumors Expressing SSTRs.

Pharmacokinetic Study of Lurbinectedin in Combination With Irinotecan in Patients With Selected Solid Tumors

Post-Authorization Safety Study (PASS) of LysaKare® in Adult Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET) Patients

BackSOM

PALACE

Trial of Nab-sirolimus in Patients With Well-differentiated Neuroendocrine Tumors (NETs) of the Gastrointestinal Tract, Lung, or Pancreas Who Have Not Received Prior Treatment With mTOR Inhibitors

To Evaluate the Optimal Dose of 68Ga-OPS202 as a PET (Positron Emission Tomography) Imaging Agent in Subjects With Gastroenteropancreatic Neuroendocrine Tumour (GEP-NET)

A Study of Famitinib in Patients With Advanced or Metastatic Gastroenteropancreatic Neuroendocrine Tumor

Lanreotide and Octreotide Long Acting Release (LAR) for Patients With Advanced Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)